Brain Tumor, Primary Clinical Trial
Official title:
Role of Glutamate-mediate Excitotoxicity in Invasion and Progression Processes of Glioblastoma Multiforme
Gliomas are the most frequent type of primary brain tumors in adults; among them glioblastoma multiforme (GBM) is the most malignant, being associated with the worst prognosis. Glutamate (Glu) is an aminoacid, responsible for essential functions in the Central Nervous System (CNS), acting both as metabolite and neurotransmitter. It is essential for regulating cellular metabolism and developmental synaptogenesis, cellular migration, differentiation and death. Recent scientific evidences have demonstrated alteration in Glu synthesis and signaling being directly involved in GBM growth and invasion
Glu and its scavenger's levels are measurable both in serum and in the cerebral-spinal fluid (CSF), thus making them ideal markers for tumor aggressiveness and disease activity as well as a potential target for new therapeutic approaches. Serum and CSF levels of glutamic oxaloacetic transaminase (GOT1), Glutamate Pyruvate Transaminase (GPT) and glutamate and aspartate levels of a total of 40 patients will be collected. Molecular biology analyses will be conducted and oncological and imaging data will be collected during follow-up in patients enrolled in the present studies. MRI imaging as well as blood sampling will be performed at definite timepoints (baseline and 3, 6 and 9 months follow-up). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06057168 -
Performance of Elucirem® in DSC-MRI Perfusion of Brain Gliomas
|
Phase 3 | |
| Recruiting |
NCT04427384 -
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
|
||
| Completed |
NCT03323450 -
Cognitive Remediation Therapy for Brain Tumor Patients: Improving Working Memory
|
N/A | |
| Completed |
NCT00241670 -
Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid
|
Phase 3 | |
| Completed |
NCT02599142 -
Comparing Immobilisation Shells in Cranial Radiotherapy
|
N/A | |
| Not yet recruiting |
NCT01445691 -
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
|
Phase 2 | |
| Recruiting |
NCT06282562 -
FeelFit: High-intensity Interval Training to Improve Self-reported Physical Fitness in Brain Tumor Patients
|
N/A | |
| Completed |
NCT00001574 -
A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients With Primary and Metastatic Brain Tumors
|
||
| Completed |
NCT04365647 -
Intra-operative Variation in Size of Brain Tumors After Craniotomy
|
||
| Withdrawn |
NCT04776980 -
Multimodality MRI and Liquid Biopsy in GBM
|
Early Phase 1 | |
| Completed |
NCT03262636 -
Two-Part Study to Evaluate the Safety and Efficacy of Image Guided Surgery Using Indocyanine Green for Intramolecular Imaging of Nervous System Tumors Compared to Standard of Care, (TumorGlow)
|
Phase 1 | |
| Active, not recruiting |
NCT02006407 -
A Pilot Study to Evaluate Neurocognitive Injury and Longitudinal Changes in White Matter During Radiation Therapy in Children With Primary Brain Tumors
|
N/A | |
| Recruiting |
NCT03213002 -
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
|
Phase 1/Phase 2 | |
| Terminated |
NCT04901806 -
Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03373487 -
Cognitive Rehabilitation in Brain Tumor Patients After Neurosurgery
|
N/A | |
| Not yet recruiting |
NCT06106997 -
Clinical Feasibility of Brain Radiotherapy Using Synthetic CTs in an MRI-only Workflow
|
N/A | |
| Recruiting |
NCT05254197 -
SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)
|
||
| Recruiting |
NCT05092802 -
The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment
|
Phase 2 | |
| Recruiting |
NCT05480644 -
Circulating Biomarkers Repository in Adults Diagnosed With Primary and Metastatic Brain Tumors
|
||
| Recruiting |
NCT05831631 -
Characterization of Circulating and Tumor-infiltrating Immune Cells in Malignant Brain Tumors
|